Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Sponsor
Novo Nordisk A/S
Study ID
NCT05890976
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants will receive semaglutide tablets orally once daily for 44 weeks.
  • Semaglutide Placebo — DRUG
    Participants will receive placebo matched to semaglutide.

Study Details

This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks. In addition to taking the medicine, participants will have talks with study staff about: * Healthy food choices * How to be more physically active * What participants can do to lose weight This study will last for about 1 year.

Key Dates

Start date
May 30, 2023
Status verified
Jan 2026
Primary completion
Jan 16, 2025
Completion
Jan 16, 2025

Study Design

Enrollment
200 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide 50 mg
    Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 44 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), 25 mg (weeks 13 to 16) and 50 mg (weeks 17 to 44).
  • Placebo Comparator: Semaglutide Placebo
    Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.

Primary Outcome Measure

Relative Change in Body Weight [ Time Frame: From baseline (week 0) to end of treatment (week 44) ]

Related Studies